Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€272.00

€272.00

-1.460%
-4.0
-1.460%
-
 
12.12.25 / Tradegate WKN: A1437N / Symbol: BGNE / Name: BeiGene / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

BeiGene Ltd ADR Stock

A loss of -1.460% shows a downward development for BeiGene Ltd ADR.
So far the community has only identified positive things for BeiGene Ltd ADR stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of BeiGene Ltd ADR in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of BeiGene Ltd ADR vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
BeiGene Ltd ADR -1.460% -2.158% -16.564% 58.140% 58.140% 38.071% 43.915%
Ardelyx Inc. 5.570% 2.840% 1.187% 5.509% 6.465% 176.349% -3.856%
Krystal Biotech 0.330% 3.678% 18.962% 25.776% 37.057% 193.803% -
Evolus Inc -4.200% -1.724% -8.065% -47.706% -45.714% -18.571% 88.742%

Comments

Prediction Buy
Perf. (%) 47.92%
Target price 285.030
Change
Ends at 03.12.25

BeiGene, Ltd. (NASDAQ: BGNE) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $300.00 price target on the stock.
Ratings data for BGNE provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 69.89%
Target price 246.194
Change
Ends at 13.11.25

BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $254.00 to $260.00. They now have a "buy" rating on the stock.
Ratings data for BGNE provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 27.45%
Target price 217.469
Change
Ends at 22.10.25

BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at JPMorgan Chase & Co. from $200.00 to $235.00. They now have an "overweight" rating on the stock.
Ratings data for BGNE provided by MarketBeat
Show more